导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.29% | 1184/4773 |
| 近一周 | -0.92% | 2204/5462 |
| 近一月 | -3.19% | 2632/5421 |
| 近一季 | -7.98% | 2775/5209 |
| 近半年 | -2.99% | 2714/4920 |
| 近一年 | 11.34% | 1007/4366 |
| 近两年 | 79.13% | 857/2954 |
| 近三年 | 45.19% | 656/2253 |
| 成立以来 | 89.54% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.54% 901/4961 |
19.47% 1294/5312 |
- - |
- - |
| 2025 | 32.48% 1181/4813 |
2.48% 1358/3635 |
2.20% 1765/4076 |
24.47% 1465/4524 |
1.61% 1303/4813 |
| 2024 | 7.73% 1629/3463 |
-2.40% 1357/2808 |
-4.85% 1573/3014 |
16.16% 1517/3129 |
-0.14% 1328/3463 |
| 2023 | -4.61% 687/2656 |
7.66% 541/2280 |
-3.75% 887/2385 |
-3.97% 1029/2515 |
-4.13% 881/2655 |
| 2022 | -16.91% 530/2207 |
-13.10% 699/1919 |
3.23% 1188/2016 |
-9.96% 329/2113 |
2.87% 812/2208 |
| 2021 | 20.68% 178/1822 |
-1.25% 455/1255 |
10.64% 447/1330 |
5.95% 249/1466 |
4.25% 345/1822 |
| 2020 | 25.91% 612/1250 |
-6.13% 458/1028 |
17.21% 384/1067 |
9.50% 646/1164 |
4.51% 836/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 博时中证500ETF联接A VS. 长安沪深300非周期A(740101) |